Use of convalescent serum reduces severity of COVID-19 in nonhuman primates

• Published in: Cell reports (Cambridge) Vol. 34; no. 10; p. 108837
• Main Authors: Cross, Robert W., Prasad, Abhishek N., Borisevich, Viktoriya, Woolsey, Courtney, Agans, Krystle N., Deer, Daniel J., Dobias, Natalie S., Geisbert, Joan B., Fenton, Karla A., Geisbert, Thomas W.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 09.03.2021; The Author(s); Elsevier
• Subjects: Animals; antibodies; Antibodies, Neutralizing - blood; Antibodies, Viral - blood; Chlorocebus aethiops - immunology; convalescent serum; coronavirus; COVID-19; COVID-19 - immunology; COVID-19 - therapy; COVID-19 - veterinary; COVID-19 - virology; COVID-19 Serotherapy; Female; Immunization, Passive - methods; Immunization, Passive - veterinary; Male; nonhuman primate; Primate Diseases - immunology; Primate Diseases - therapy; Primate Diseases - virology; Primates - immunology; SARS-CoV-2; SARS-CoV-2 - immunology; Viral Load; viral pneumonia; COVID-19; SARS-CoV-2; convalescent serum; coronavirus; nonhuman primate; antibodies; viral pneumonia

Passive transfer of convalescent plasma or serum is a time-honored strategy for treating infectious diseases. Human convalescent plasma containing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently being used to treat patients with coronavirus disease 2019 w...